Fig. 2

Vangl1 and Vangl2 overexpression promote breast cancer cell migration and potentiate Wnt/PCP signaling. a, b Representative brightfield images of migrating NDL cells stably expressing Vector, Vangl1, or Vangl2 at 0 and 12 h, scale bar = 200 µm (a) and leading-edge dynamics at 12 h, scale bar = 50 µm (b). c Relative cell migration quantification of BT549, Met-1, NDL and MCF7 cells stably expressing Vector or Vangl1 (BT549 n = 5, p = 0.0001, Met-1 n = 3, p = 0.0339, NDL n = 6, p = 0.0108, MCF7 n = 7, p = 0.0035,). d Relative cell migration quantification of BT549, MDA-MB-231, Met-1, NDL, and MCF7 cells stably expressing Vector or Vangl2 (BT549 n = 3, p = 0.0210, MDA-MB-231 n = 3, p = 0.0050, Met-1 n = 3, p = 0.0412, NDL n = 8, p = 0.0049, MCF7 n = 8, p = 6.17E-05). e–f NDL and Met-1 cells stably expressing Vector, Vangl1 or Vangl2 blotted for Dvl2 (e) and quantification of Dvl2 phosphorylation in NDL and Met-1 cells stably expressing Vector, Vangl1 or Vangl2 (f) (NDL-Vangl1 n = 3, p = 0.0291, NDL-Vangl2 n = 6, p = 0.0453, Met-1-Vangl1 n = 5, p = 0.0009, Met-1-Vangl1 n = 3, p = 0.0119). g, h NDL cells stably expressing Vector, Vangl1, or Vangl2 treated with DMSO or 100 nM C59 for 24 h blotted for Dvl2 (g) and quantification of relative Dvl2 phosphorylation (h). Bar graphs represent the mean ± sem of experimental replicates (n). Significance was determined by a two-sided unpaired t test with Welch’s correction, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001